BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, Chen YY, Yang CW, Wu SS, Chou KC. Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS One 2020;15:e0237582. [PMID: 32790715 DOI: 10.1371/journal.pone.0237582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2020;63:11034-44. [PMID: 32881503 DOI: 10.1021/acs.jmedchem.0c00956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Boonma T, Nutho B, Darai N, Rungrotmongkol T, Nunthaboot N. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study. J Biomol Struct Dyn 2021;:1-12. [PMID: 33430709 DOI: 10.1080/07391102.2020.1869587] [Reference Citation Analysis]
4 Scotto R, Buonomo AR, Moriello NS, Maraolo AE, Zappulo E, Pinchera B, Gentile I, Borgia G. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. RRCT 2019;14:173-82. [DOI: 10.2174/1574887114666190306154650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
5 Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis 2021;53:612-9. [PMID: 32917546 DOI: 10.1016/j.dld.2020.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Boonma T, Nutho B, Rungrotmongkol T, Nunthaboot N. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective. Comput Biol Chem 2019;83:107154. [PMID: 31751885 DOI: 10.1016/j.compbiolchem.2019.107154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Randolph JT, Li T, Chris Krueger A, Heyman HR, Chen HJ, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin M, Krishnan P, Wagner R, DeGoey DA. Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett 2020;30:126986. [PMID: 32046903 DOI: 10.1016/j.bmcl.2020.126986] [Reference Citation Analysis]
8 Sun HY, Cheng CY, Lin CY, Yang CJ, Lee NY, Liou BH, Tang HJ, Liu YM, Lee CY, Chen TC, Huang YC, Lee YT, Tsai MJ, Lu PL, Tsai HC, Wang NC, Hung TC, Cheng SH, Hung CC. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol 2022; 28(11): 1172-1183 [DOI: 10.3748/wjg.v28.i11.1172] [Reference Citation Analysis]